CG MedTech Co.,Ltd.

056090 KRX Technology Technology
KOSDAQ
₩1,190.00
+0.00%
Delayed · cached 15 min

Fair value analysis

056090
CG MedTech Co.,Ltd.
TechnologyTechnology
₩1,190.00
Close used for this calculation
₩966.16Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
38/100
Profitability8/25
Returns4/25
Balance Sheet15/25
Efficiency11/25
Growth0/25
Average
Quality radar
38Prof.8/25Ret.4/25Eff.11/25B.Sht15/25Growth0/25

Consensus fair value

₩966.16
Above FV
▼ -18.8% against the close used
Model range ₩355.83 – ₩1,260.00
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩355.83Fair value₩966.16Bull₩1,260.00
FairClose
52-week traded range
52W low ₩864.0052W high ₩3,350.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

CG MedTech Co.,Ltd. closed at ₩1,190.00, 23.2% above the consensus fair value of ₩966.16 drawn from 7 valuation models.

Financial DNA score 38/100 — Average. P/E of 18.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₩1,180.78
-0.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩1,134.75
-4.6%
√(22.5 × EPS × BVPS)
EPS=63, BVPS=908.4 · outside Graham range (P/E 18.9, P/B 1.3) — asset-light, treat as a rough floor
P/E Fair Value
₩1,260.00
+5.9%
EPS × 20x (sector P/E)
EPS=63, Sector P/E=20x
EV/EBITDA
₩355.83
-70.1%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=3.81B
Book Value (P/B)
₩508.70
-57.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=908.4, ROE=6.9%, g=3%, r=10%
Reverse DCF
₩1,190.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 6.4% | Historical: 0%
Margin of Safety
₩893.88
-24.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1191.84, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.